Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




AI-Enabled Chest X-Ray Solution Identifies Heart Failure Risk

By HospiMedica International staff writers
Posted on 02 Oct 2023

Heart failure is often a difficult condition to diagnose correctly because its symptoms can be quite vague. More...

Now, a novel chest X-ray algorithm can screen for telltale signs of heart failure, such as an enlarged cardiothoracic ratio (CTR) and fluid in the lungs, along with other indicators visible on X-rays. This development represents a significant leap forward in the fields of medical imaging and heart care, offering a new method for early detection of heart failure via automated analysis of chest X-rays.

The qXR-CTR artificial intelligence (AI)-enabled chest X-ray solution from Qure.ai Technologies (New York, NY, USA) is an AI-powered solution designed to assist doctors in both hospital and clinic settings by automating the measurement of the CTR on chest X-rays. Specifically, it calculates the ratio of the maximum transverse diameter of the heart to the maximum inner transverse diameter of the thoracic cavity, providing the most accurate indicator of cardiomegaly on plain film. By employing advanced AI algorithms, the technology offers quick and accurate results, saving valuable time for healthcare professionals and enhancing the reliability of diagnoses.

Qure.ai has now received FDA clearance for measuring the CTR utilizing qXR-CTR, marking the company's 12th FDA-cleared algorithm. Qure.ai’s previous FDA-cleared findings include endotracheal tube location, tracheostomy tube location, pneumothorax, and pleural effusion identification for CXR; qER for intracranial hemorrhage detection on head CT scans, and qER Quant for quantifying serious abnormalities on head CT scans.

"We are delighted to receive FDA clearance for qXR-CTR,” said Prashant Warier, Co-Founder and CEO at Qure.ai. “This cutting-edge algorithm enhances the accuracy and efficiency of CTR assessment and empowers healthcare professionals with a valuable tool to diagnose and monitor risk of heart failure. This achievement reaches an industry record for the greatest number of FDA-cleared findings on CXR scans, demonstrating Qure.ai's commitment to advancing better patient outcomes through AI-driven solutions."

Related Links:
Qure.ai Technologies


Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Temperature Monitor
ThermoScan Temperature Monitoring Unit
Blood Bank Refrigerator
MBR-705GR-PE
Gynecological Examination Chair
arco-matic
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.